Release Summary

Dicerna today announced that new clinical data from a Phase 1 study of DCR-MYC in patients with solid tumors, multiple myeloma, or lymphoma will be presented at the 2015 ASCO Annual Meeting.

Dicerna Pharmaceuticals, Inc.